125 related articles for article (PubMed ID: 17267660)
21. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
24. Teratoid Wilms' tumor: case report of a rare variant that can mimic aggressive biology during chemotherapy.
Treetipsatit J; Raveesunthornkiet M; Ruangtrakool R; Sanpaki K; Thorner PS
J Pediatr Surg; 2011 Dec; 46(12):e1-6. PubMed ID: 22152898
[TBL] [Abstract][Full Text] [Related]
25. The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms' tumor. A report from the National Wilms' Tumor Study.
Green DM; Breslow NE; Evans I; Moksness J; Finklestein JZ; Evans AE; D'Angio GJ
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):207-12. PubMed ID: 8037337
[TBL] [Abstract][Full Text] [Related]
26. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation.
Tsuchida K; Tsujita T; Hayashi M; Ojima A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kikuchi H; Oshima Y; Suzuki M; Yamamoto M
Free Radic Biol Med; 2017 Feb; 103():236-247. PubMed ID: 28039084
[TBL] [Abstract][Full Text] [Related]
27. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
Nagler A; Miao HQ; Aingorn H; Pines M; Genina O; Vlodavsky I
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):194-202. PubMed ID: 9012656
[TBL] [Abstract][Full Text] [Related]
30. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S; Haase G; Ritchey M; Kelalis P; D'Angio GJ
J Clin Oncol; 1998 Dec; 16(12):3744-51. PubMed ID: 9850017
[TBL] [Abstract][Full Text] [Related]
31. Preoperative chemotherapy in the management of intracaval extension of Wilms' tumor.
Crombleholme TM; Jacir NN; Rosenfield CG; Lew S; Harris BH
J Pediatr Surg; 1994 Feb; 29(2):229-31. PubMed ID: 8176597
[TBL] [Abstract][Full Text] [Related]
32. Wilms' tumor in the neonate: a report from the National Wilms' Tumor Study.
Hrabovsky EE; Othersen HB; deLorimier A; Kelalis P; Beckwith JB; Takashima J
J Pediatr Surg; 1986 May; 21(5):385-7. PubMed ID: 3012057
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Abramovitch R; Dafni H; Neeman M; Nagler A; Pines M
Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487
[TBL] [Abstract][Full Text] [Related]
34. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
35. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
38. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
Shigemura K; Arbiser JL; Sun SY; Zayzafoon M; Johnstone PA; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LW
Cancer; 2007 Apr; 109(7):1279-89. PubMed ID: 17326044
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
40. Halofuginone: an inhibitor of collagen type I synthesis.
Granot I; Halevy O; Hurwitz S; Pines M
Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
